SYNERGISTIC CONVERGENCE: EXPLORING COMBINATIONS OF DIVERSE PHYSIOLOGICAL ACTIVITIES – A REVIEW
AbstractThe development of effective therapeutic strategies for various remedial conditions often involves the exploration of synergistic interaction between two pharmacophores. The most frequent methods for multidrug therapy combining two or more active ingredients into a single, and creating hybrid molecular entities that can modulate numerous targets interaction gives a synergistic effect. As a result, the structural activity relationship is becoming more and more common in the form of hybrid molecules (multiple ligand approach) such as chalcone-isatin, ferrocene-isatin as well as ferrocene-chalcone combinations possesses multiple biological properties such as antitubercular, anticancer, antibacterial, Antimalarial, anti-inflammatory which having synergistic activity due to their combination as well as their substitutions like electron donating and withdrawing group. The evaluation of synergistic drug combinations offers promise in overcoming challenges such as drug resistance, dose-dependent toxicity, and suboptimal treatment responses. To determine the significance of the notion of molecular hybridization, the pharmacological potency of the hybrid molecules is compared to those of their separate counterparts. This review underscores the promising role of chalcone-isatin, ferrocene-isatin and ferrocene-chalcone hybrids as versatile agents with a broad spectrum of physiological activities. These compounds offer a myriad of opportunities for innovative drug design and development, making them a captivating area of research in modern pharmacology and medicinal chemistry as well as they give a synergistic effect on different target systems.
Article Information
1
2875-2894
942 KB
154
English
IJPSR
Sakshi Nandkumar Patil *, Vaishali Nagulwar and Sanket Nandkumar Patil
Department of Pharmaceutical Chemistry, Government College of Pharmacy, Chh. Sambhajinagar, Maharashtra, India.
Sakshipatil112000@gmail.com
27 March 2024
22 May 2024
24 May 2024
10.13040/IJPSR.0975-8232.15(10).2875-94
01 October 2024